The company develops and manufactures antibody and other protein products to treat cancer, immunological and inflammatory disorders and infectious diseases. the company's development program includes neuprex(tm), synthetic peptides derived from bpi, for treatment of fungal and other infections and e5(r), a monoclonal antibody for the treatment of gram-negative sepsis.